Dr. Herman Weiss
Sep 20, 2026
Welcome back to the Pause Collective Science Review - the twice-weekly scan where I read the new research so you don't have to. This week's window (September 14-18) brought something new: for the first time, this review covers PMOS (the condition we used to call PCOS) alongside menopause, because these two audiences are one community. More and more, the science says the same thing.
1. Hormone therapy and liver cancer: 24 years of follow-up finally answers the question
What it studied. Researchers went back to the two big Women's Health Initiative hormone therapy trials - over 27,000 postmenopausal women randomized to estrogen-alone, estrogen-plus-progestin, or placebo - and asked a question no randomized trial had answered: does menopausal hormone therapy change the risk of primary liver cancer? They followed participants for nearly 24 years.
What it found. Reassuring, mostly. Seventy-four liver cancers occurred in total, with no significant difference between hormone therapy and placebo in either trial. Estrogen-plus-progestin did not increase liver cancer deaths. One subgroup signal deserves honesty rather than spin: among women aged 50-59, and among women who had used oral contraceptives in the past, the combination therapy group showed more liver cancers (10 vs 0 in the younger subgroup). The numbers are tiny, and the authors themselves call it a signal that "warrants further investigation," not a conclusion.
What it means. If you've seen liver-cancer scares attached to hormone therapy, this is the best evidence we have, and it's largely reassuring. The subgroup finding is exactly the kind of thing that should be studied more - not a reason to panic, and not a reason to dismiss.
Its limits. Liver cancer is rare, so even 24 years of WHI data gives us only 74 cases - the confidence intervals are wide, and the subgroup analyses are exploratory. These trials also used older oral formulations (conjugated equine estrogen with medroxyprogesterone acetate), not the transdermal estradiol and micronized progesterone most women use today.
One note for our readers with a PMOS history: the liver is ground zero for the metabolic side of PMOS - fatty liver disease is markedly more common in this group. Whether hormone therapy behaves any differently on an already metabolically stressed liver is genuinely unknown; this trial can't tell us. Worth raising with your doctor if it applies to you. (That's my inference from the population difference, not something this study measured.)
Citation: Pichardo MS, Aragaki AK, Manson JE, et al. Menopausal hormone therapy and primary liver cancer: long-term follow-up of the Women's Health Initiative randomized trials. British Journal of Cancer, 2026. https://www.nature.com/articles/s41416-026-03621-9
2. Not all estrogen receptors are the same - and that might explain a lot
What it studied. A systematic review and meta-analysis in BMC Women's Health pooled 13 randomized trials (1,115 menopausal women) of therapies that target specific estrogen receptor subtypes - ERalpha versus ERbeta - including SERMs, estetrol, and plant-derived "phyto-SERMs." The question: do receptor-selective treatments relieve hot flashes, mood symptoms, and bone loss differently?
What it found. Overall, ER-targeted therapies improved menopausal symptom burden, hot flashes, anxiety, and depressive symptoms compared with placebo. The exploratory subgroup pattern is the interesting part: ERbeta-preferring treatments looked more consistent for symptom relief, while ERalpha-predominant modulation showed possible skeletal benefits but limited symptom effect.
What it means. This is early evidence for an idea with real potential: matching the treatment to the receptor, not just "estrogen or no estrogen." If it holds up, it could eventually mean better-targeted options for women who can't or won't use conventional hormone therapy.
Its limits. The authors are admirably blunt: heterogeneity across studies was very high (I-squared over 90%), the depression result didn't survive sensitivity analysis, and the ERalpha conclusion rests on a single raloxifene trial. Their own verdict - "hypothesis-generating rather than clinically confirmatory" - is the right one. File this under "watch this space," not "change your prescription."
Citation: Wan M, Wei J, Hu J, et al. Targeting estrogen receptor subtypes in menopausal syndrome: differential effects on vasomotor symptoms, mood, and bone health - a systematic review and meta-analysis. BMC Women's Health, 2026. https://link.springer.com/article/10.1186/s12905-026-04849-6
3. What a mother's PMOS means for her children - and the answer is different for sons and daughters
What it studied. A prospective study from the Chinese University of Hong Kong, published in Fertility and Sterility, followed 71 women with PMOS and their 86 children (aged 15-25), comparing them with over 500 mothers without PMOS and their children. Offspring got detailed workups: body measurements, blood pressure, glucose, insulin, lipids, reproductive hormones.
What it found. The impact cascades a generation, but splits by sex. Daughters of PMOS mothers showed the reproductive signature early: 11% already met PMOS criteria (vs 0% of controls), menstrual irregularity ran at 58% vs 16%, and elevated androgens at 50% vs 26%. Sons showed the metabolic signature instead: hypertension and metabolic syndrome at roughly four times the control rate. A subtle finding with long shadows: the young people's blood glucose still looked normal, but markers of their insulin secretion were already lower - the pancreas compensating today, with less reserve for tomorrow.
What it means. PMOS is a family health condition, not only a women's health condition. If you have PMOS, your daughter's irregular cycles and your son's blood pressure deserve earlier attention than standard screening timelines suggest.
Its limits. One hundred and seventy-two offspring, one center, one population (Hong Kong Chinese families) - the effect sizes are large but the sample is small, and 15-25 is early; we don't yet know how these trajectories play out at 40 or 50. And association within families isn't proof of cause - shared genes, shared diet, and shared environment all travel together.
And here's where this community's two halves meet. Many women with PMOS are now approaching perimenopause carrying two decades of insulin resistance - the compounding risk I wrote about in my PMOS-to-perimenopause series. This study says their children may be starting adulthood with less metabolic reserve of their own. That's not a reason for fear; it's an argument for making metabolic screening a family habit rather than an individual afterthought.
Citation: Ng NYH, Chung JPW, Ma RCW, et al. Fertility and Sterility, 2026 (reported via CU Medicine, September 14, 2026). https://med.cuhk.edu.hk/press-releases/cuhk-reveals-health-risks-of-pmos-on-offspring-daughters-face-reproductive-issues-sons-face-much-higher-metabolic-risks
What social media is talking about this week
The first PMOS Awareness Month under the new name. September has always been PCOS Awareness Month; this is the first one since the May renaming, and mainstream outlets are running explainers under the new name (FOX 5 Atlanta, WESH, ELLE Singapore, among others). The vocabulary is genuinely spreading. What I like: most of these pieces lead with the metabolic story, which is the whole point of the new name. This is grounded - I read the coverage.
"I cut one food and lost 21kg." The Mirror ran a PMOS weight-loss testimonial this week, and social feeds are full of the genre: one food eliminated, transformation achieved. I'm glad for anyone feeling better, but there is no single-food cure in any PMOS guideline, and these stories quietly sell the idea that you failed if the same trick didn't work for you. The evidence supports overall dietary pattern, resistance training, sleep, and sometimes medication - boring, compound, and real. Grounded on the coverage; the genre characterization is my read of the current feeds.
Testosterone for women keeps surging. After Wednesday's FDA public meeting, coverage of testosterone prescribing for menopausal women - and the denials and delays women face getting it - ran across Reuters, CNN, and the Independent this week. I published a full breakdown of the FDA meeting here on Friday, so I won't repeat it; the social chatter matches what the data says about rising use, and the access complaints women are posting are consistent with the coverage.
The "PMOS gives you cancer" headlines. An EMJ piece this week highlights a large US insurance-database study: women with PMOS had 5.76 times the adjusted hazard of uterine cancer, with elevated hazards for ovarian, cervical, and breast cancers too. Two honest caveats before anyone spirals: the underlying study dates from May, not this week, and these are relative risks from an observational database - uterine cancer in young women is rare, so even a multiplied hazard stays a small absolute number, and association is not causation. The legitimate takeaway is the one the guidelines already give: if you have PMOS and long gaps between periods, that symptom deserves treatment, not just tolerance.
The estrogen patch shortage hasn't gone away. Coverage continued this week (ClearHealthCosts ran an explainer on the 17th). I flagged this in Issue 1; it remains a live problem, and if your pharmacy is out, ask about equivalent alternatives rather than going without - that's a conversation worth having now, not at the refill counter.
A quick note on process: two studies you may have seen covered elsewhere this week - the "menopause brain changes take a break" MRI work (van't Hof, Nature Communications) and the earlier-menopause/faster-brain-aging analysis - were both reviewed in Issue 1, so they're not re-annotated here. And the NICE draft guideline adopting the PMOS name gets its own dedicated post this weekend, not a rehash here.
Until Tuesday - read the science, keep the skepticism.
Dr. Herman Weiss
Medical Disclaimer
The information provided in this blog post and newsletter is for educational and informational purposes only. It does not constitute medical advice or professional services and should not be used to diagnose or treat any health problem or disease. Always seek the advice of your physician or other qualified health-care provider regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read here.
Use of this content does not create a doctor-patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.